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Associations with kidney transplant survival
and eGFR decline in children and young
adults in the United Kingdom: a
retrospective cohort study
Alexander J. Hamilton1* , Lucy A. Plumb1,2, Anna Casula2 and Manish D. Sinha3,4
Abstract
Background: Although young adulthood is associated with transplant loss, many studies do not examine eGFR
decline. We aimed to establish clinical risk factors to identify where early intervention might prevent subsequent
adverse transplant outcomes.
Methods: Retrospective cohort study using UK Renal Registry and UK Transplant Registry data, including patients
aged < 30 years transplanted 1998–2014. Associations with death-censored graft failure were investigated with
multivariable Cox proportional hazards. Multivariable linear regression was used to establish associations with eGFR
slope gradients calculated over the last 5 years of observation per individual.
Results: The cohort (n = 5121, of whom n = 371 received another transplant) was 61% male, 80% White and 36%
had structural disease. Live donation occurred in 48%. There were 1371 graft failures and 145 deaths with a
functioning graft over a 39,541-year risk period. Median follow-up was 7 years. Fifteen-year graft survival was 60.2%
(95% CI 58.1, 62.3).
Risk associations observed in both graft loss and eGFR decline analyses included female sex, glomerular diseases,
Black ethnicity and young adulthood (15–19-year and 20–24-year age groups, compared to 25–29 years). A higher
initial eGFR was associated with less risk of graft loss but faster eGFR decline. For each additional 10 mL/min/1.73m2
initial eGFR, the hazard ratio for graft loss was 0.82 (95% CI 0.79, 0.86), p < 0.0001. However, compared to < 60 mL/
min/1.73m2, higher initial eGFR was associated with faster eGFR decline (> 90 mL/min/1.73m2; − 3.55 mL/min/
1.73m2/year (95% CI -4.37, − 2.72), p < 0.0001).
Conclusions: In conclusion, young adulthood is a key risk factor for transplant loss and eGFR decline for UK
children and young adults. This study has an extended follow-up period and confirms common risk associations for
graft loss and eGFR decline, including female sex, Black ethnicity and glomerular diseases. A higher initial eGFR was
associated with less risk of graft loss but faster rate of eGFR decline. Identification of children at risk of faster rate of
eGFR decline may enable early intervention to prolong graft survival.
Keywords: Kidney transplant, Child, Adolescent, Young adult, Graft survival, eGFR
© The Author(s). 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License,
which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if
changes were made. The images or other third party material in this article are included in the article's Creative Commons
licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons
licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain
permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the
data made available in this article, unless otherwise stated in a credit line to the data.
* Correspondence: alexander.hamilton@bristol.ac.uk
1Population Health Sciences, University of Bristol, G.04, Canynge Hall, 39
Whatley Road, Bristol BS8 2PS, UK
Full list of author information is available at the end of the article
Hamilton et al. BMC Nephrology          (2020) 21:492 
https://doi.org/10.1186/s12882-020-02156-2
Background
Kidney transplantation is the optimal treatment for end
stage kidney disease (ESKD) in children and young
adults as it provides them the best opportunity for nor-
mal growth and development, a better quality of life and
places fewer restrictions on daily activities [1]. For health
service providers, transplantation is also the most cost-
effective kidney replacement therapy (KRT) modality [2].
Young adulthood though remains a distinct period for
risk of graft loss. A large registry study analysing the ef-
fect of age identified graft failure rates were highest at
19 years and that those aged 17–24 years were at the
highest risk of graft failure [3], with similar findings from
other studies not including patients from the UK [4–7].
This may be because both adolescence and young adult-
hood are associated with increased risk-taking behaviour,
poor medication compliance and changes to care as pa-
tients transfer to adult services [3, 5]. Furthermore, brain
development continues during young adulthood [8],
which may impact reasoning and decision-making. Thus,
following periods of stable graft function, typically, this
may be followed by period of worsening graft function
and potential sudden graft failure.
There are few studies including data reporting UK
graft survival for children and young adults. These
data are though limited for their generalisability as
one reported outcomes for transplants between 1973
and 2000 [9] and another described outcomes for de-
ceased donor transplant recipients alone [10]. Two
further reports have data on short term outcomes
limited to 3–5 years with a specific focus on HLA
mismatching: non-inferiority of poorly matched living
donor transplants compared to well-matched deceased
transplants suggested by one [11], with opposing evi-
dence for this in the larger Collaborative Transplant
Study dataset [12]. A recent study reported graft loss
outcomes for UK young adults using Hospital Episode
Statistics and Office for National Statistics data and
showed an increased risk of graft loss relative to
other age groups for those aged 14–23 years with 10-
year follow up [13].
Although it is unlikely that outcomes during adoles-
cence and young adulthood will differ for UK individ-
uals, to our knowledge no studies have evaluated the
role of initial transplant function or examine risk factors
for declining function. Importantly, studies have been
limited in their focus and duration of follow up, with the
maximum period of follow up limited to 10 years. This
follow-up period is relevant as between 2000 and 2011,
UK children received live and donation after brain death
kidney transplants at a mean age of 11 ± 5 years [11].
The median age at transfer to adult services in the UK is
18 years [14]. Therefore following 10 years of follow up a
large proportion would not yet have transferred and
many would be under the age of 24 years, reported as
the upper limit of the high-risk age window [3].
In this study, we aimed to use explanatory regression
models to establish clinical characteristics for early iden-
tification of those at risk of declining transplant function
and failure using data collected across two major regis-
tries that include all children and young adults with fol-
low up data extending beyond childhood and > 10 years
where available. This would allow for the development
of targeted interventions intending to preserve trans-
plant function and prevent graft loss. We report graft
survival for UK children and young adults and to explore
the importance of clinical donor and recipient variables
not only for graft loss but also rate of decline, among
grafts of varying vintage. To our knowledge, factors asso-
ciated with graft function decline in children and young
adults have not previously been evaluated. Clinical iden-
tification of eGFR decline is time-critical for this group
and intervention often requires a biopsychosocial
approach.
Methods
We undertook a retrospective cohort study using linked
UK Renal Registry (UKRR) and NHS Blood and Trans-
plant (NHSBT) data, including children and young
adults aged < 30 years who underwent kidney transplant-
ation between 1998 and 2014. As UKRR and NHSBT
datasets differ, their combination provided comprehen-
sive clinic-demographic data with greater completeness
and reliability.
Clinical data from the UKRR and NHSBT
The UKRR collects data on all patients receiving KRT
from UK adult and pediatric kidney units [15, 16]. It has
been granted a section 251 exemption by the Health Re-
search Authority, allowing the registration of identifiable
patient information from kidney units without first ask-
ing individual patient consent. We defined exposures
and covariates in a research protocol and applied for
data in October 2017, receiving approval in February
2018. The data was received December 2018–March
2019. The study included all patients aged < 30 years
who received a kidney transplant from 01/01/1998 to
31/12/2014. These dates were chosen to reflect full
coverage UK kidney units and to ensure at least 1 year
of individual follow-up time. Biochemical data was ex-
tracted up to the final quarter of 2016. Initial eGFR was
calculated from the first biochemical data recorded fol-
lowing transplantation; returns are annual for paediatrics
and quarterly for adults. Patients may have previously
received a transplant prior to the study period.
NHSBT is a special health authority supporting UK
organ transplantation and collects data on transplant
outcomes for the UK Transplant Registry (UKTR).
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Informed consent for data collection is obtained from
recipients and donor next of kin. We applied for data in
November 2017. The data was extracted in October
2018 and included follow-up to this time point, hence
was the most recent and used in analyses. NHBT de-
scribes human leucocyte antigen (HLA) mismatches ac-
cording to the UK 2006 National Kidney Allocation




We modelled death-censored graft failure over death as
a competing risk, as this is felt to be more appropriate
for an aetiological research question [18], aiming to
identify clinical risk factors. Univariate analyses included
Kaplan-Meier survival curves and log-rank tests. We
used a conditional risk-set model for multiple failure
data [19]. This measures time to event from the time of
the previous event, with follow-up time reset to zero
after each failure event where patients were re-
transplanted. So, when retransplanted, the same individ-
ual appears twice in the data, as follows:
ID Graft number Entry time Exit time Censored
1 1 0 2.17 1
1 2 0 13.9 0
By using a multivariable Cox proportional hazards model,
we explored the association of evidence-based variables as
well as initial eGFR post-transplant on the risk of death-
censored graft failure [hazard ratio (HR) (95% confidence
interval (CI)), p-value]. We analysed age group as time-
varying and used stratification by graft number, clustering
at the participant level (to account for some participants
appearing more than once in the dataset) and Efron’s
method for handling ties [20]. We tested for the assump-
tion of proportionality using visual plots, Schoenfeld resid-
uals and testing for a log–time interaction. As some
indication of non-proportionality was observed for glom-
erular diseases versus other kidney diseases, we also per-
formed piecewise Cox regression to confirm the results.
eGFR trend
We chose to explore eGFR decline assuming linearity
given that this is a widely used and well-established
method [21–23]. We calculated estimated glomerular fil-
tration rate (eGFR) using the Schwartz formula [24] if
aged < 18 years and the 4-variable Modification of Diet
in Renal Disease formula [25] otherwise. Although it has
been suggested to average pediatric and adult serum
Creatinine-based eGFR equations for those aged 18–26
years [26], our approach reflects current UK clinical
practice. Where height was missing, the previous entry
was substituted. Where ethnicity was missing, white eth-
nicity was substituted. For participants with ≥3 eGFR
values outside the first 6 months post-transplant, indi-
vidual linear regressions (least squares) of eGFR against
time were performed using the most recent 5 years of
data per participant. For example, for someone trans-
planted in 2005 with a functioning graft throughout the
study period, we used data from 2012 to 2016. Analysis
of patient-level eGFR slopes suggested that linear model-
ling provided a reasonably accurate fit for the time-
period of kidney function explored. Using the most re-
cent 5 years of observation resulted in greater linearity
than using all available data and less combined use of
eGFR equations in the same individual. Since eGFR was
calculated to create a regression line, the equation used
was of less importance as regression line gradients would
be similar, and the regression line would smooth any
missing eGFR values. For quarterly data, the data collec-
tion quarter mid-point was used.
We used backward elimination and examined
explanatory variables in univariate models to establish
associations with eGFR slope gradients. We combined
associated variables (p < 0.05) in a multivariable linear
(least squares) regression model and removed explanatory
variables from the final model if there was no statistical
association when co-adjusted, having checked that this did
not affect the regression coefficients of the remaining vari-
ables. We checked for assumptions of linearity between
continuous variables and the outcome variable, evidence
of heteroscedasticity and normally distributed residuals
with a mean of zero. Where non-linear, continuous vari-
ables were categorised into clinically relevant groups. We
tested for potential pre-specified interactions: 1) sex and
primary kidney disease, 2) initial eGFR and sex, 3) ethni-
city and primary kidney disease, 4) initial eGFR and ethni-
city (as ethnicity contributes to eGFR equations). Data are
reported appropriate to their distribution. We used Stata
v.15 for our analyses.
First eGFR post-transplant
Data returns to the UKRR are annual for paediatric
patients and quarterly for adult patients. The first serum
creatinine result reported to the UKRR post-transplant
for paediatrics is at 3 months (alongside a height meas-
urement) and within the first 3 months for adults. These
data were used to derive the first eGFR measurement in
the first 3 months following transplantation, thus reflect-
ing early steady state.
Results
Completeness was high for most items (Table 1). Deaths
were discordant between UKRR and UKTR datasets. All
Hamilton et al. BMC Nephrology          (2020) 21:492 Page 3 of 13
Table 1 Patient and transplant characteristics
Variable Total n n %
Male sex 5121 3107 60.7
Ethnic group




Primary kidney disease groupa
Glomerular disease 5065 1467 29.0
Systemic diseases affecting the kidney 304 6.0
Familial/hereditary nephropathies 593 11.7
Tubulointerstitial disease 1808 35.7
Miscellaneous kidney disorders 893 17.6
Late presentationb 3366 867 25.8
Age when first seen (years) (median, IQR) 3389 13.1 2.7, 20.0
Age at KRT start (years) (median, IQR) 5085 19.1 12.9, 24.1
Years to KRT start from first nephrology review (median, IQR) 3370 2.0 0.2. 5.4
Tertiles of year started KRT (median, IQR) 5085 2006 2001, 2009




Haemodialysis 5102 2011 39.4
Peritoneal dialysis 1839 36.0
Transplant 1252 24.5
Age at transfer (years) (median, IQR) 1455 18 17.4, 18.5
Died 5121 260 5.1
Age at death (years) (median, IQR) 260 27.6 20.3, 32.3
Transplanted during study period
Graft 1 4750 4377 85.5
Graft 2 371 7.2
Graft 3 2 0.04
Re-transplanted during study period
Graft 2 371 369 7.2
Graft 3 2 0.04
Time from listing to transplant (years) (median, IQR) 4416 0.8 0.3, 1.8
Year of transplant




Live donation 5121 2462 48.1
Donation after brainstem death 2356 46.0
Donation after circulatory death 303 5.9
Donor age (years) (median, IQR) 5115 41 27, 49
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patients with a coded UKTR death and no UKRR death
(n = 32) died after the final date in the UKRR data
extraction. Almost all the patients with a coded UKRR
death and no UKTR death (n = 45) died after the follow-
up time for graft and patient outcomes in the UKTR
data. The remaining patient (n = 1) had biochemical data
submitted after the death date and is a likely error. As
the UKTR outcome data was used this did not affect the
graft loss analysis.
Clinical characteristics are displayed in Table 1,
with additional detail in Supplemental Table 1. The
cohort (n = 5121) mostly included one graft during
the study period (n = 4750, this was predominantly
the patient’s first ever transplant (n = 4377) but it
may have been their second (n = 371) or third (n = 2)
kidney). Seven percent (n = 371) received an
additional transplant during the study period,
primarily the patient’s second transplant (n = 369)
with third transplants being uncommon (n = 2). The
median age at the patient’s first transplant was 21
years (interquartile range (IQR) 14, 26). The cohort
was 61% male, 80% white and 36% had ESKD due to
structural kidney disorders. A quarter started KRT
within 90 days of their first nephrology review. Pre-
emptive transplantation occurred in 25%. Median kid-
ney transplant waitlist time was 0.8 years (IQR 0.3,
1.8). Participants lived a median of 26.2 km (IQR 10.7,
54.8) from their transplant centre. Live donation oc-
curred in 48%. Median cold ischaemic time was 9.3 h
(IQR 2.8, 16.3). HLA matching was considered ‘good’
(either no mismatches or 0 HLA-DR and 0/1 HLA-B
mismatch) in 50% [17]. Mean first eGFR was 62 mL/
min/1.73m2 (see Table 1 footnote), with a mean lin-
ear change of − 3 mL/min/1.73m2/year over the most
recent five years of follow-up.
There were 1371 graft failures and 145 deaths with a
functioning graft over a 39,541-year risk period. Median
follow-up was 7 years. Graft survival was as follows: 1-
year 94.4% (95% CI 93.7, 95.0), 5-year 84.0% (95% CI
82.9, 85.0), 10-year 71.1% (95% CI 69.6, 72.5), 15-year
60.2% (95% CI 58.1, 62.3) and 20-year 51.2% (95% CI
47.6, 54.7%). Graft survival varied by age at transplant
Table 1 Patient and transplant characteristics (Continued)
Variable Total n n %
Cold ischaemic time (hours) (median, IQR) 4651 9.3 2.8, 16.3
Calculated reaction frequency (%) (median, IQR)c 5118 0 0, 12
HLA mismatch groupd
0 mismatches 5120 544 10.6
[0 HLA-DR and 0/1 HLA-B] mismatches 2016 39.4
[0 HLA-DR and 2 HLA-B] or [1 HLA-DR and 0/1 HLA-B] mismatches 2272 44.4
[1 HLA-DR and 2 HLA-B] or [2 HLA-DR] mismatches 288 5.6
First eGFR (mL/min/1.73m2) (mean, SD)e 4882 62 23
Rate of eGFR change (mL/min/1.73m2/year) (mean, SD) 4487 −3.14 7.69
Graft failure 5111 1376 26.9
Follow up time (years) (median, IQR) 5111 7.0 4.0, 10.9
Time to event (years) (median, IQR) 1376 4.2 1.5, 7.6
Patient death 4750 238 5.0
Follow up time (years) (median, IQR) 4750 8.8 5.1, 13.0
Time to event (years) (median, IQR) 238 6.6 3.0, 10.6
Age at event (mean, SD) 5111 27.5 8.7
IQR interquartile range, KRT kidney replacement therapy, SD standard deviation, HLA human leucocyte antigen, eGFR estimated glomerular filtration rate
Ages are based on dates of birth rounded to mid-month
aPrimary kidney disease was using a 2012 European coding system [27]. The pediatric diagnosis was used where discordant between pediatric and adult
databases [28]
bLate presentation defined as ≤90 days from first nephrology review to RRT start
cCalculated reaction frequency is defined as the percentage of ABO-identical patients within the donor pool that are HLA incompatible with an individual patient
and is dependent on blood group and antibodies [29]
dHLA mismatch groups were derived from the UK 2006 National Kidney Allocation scheme [17]. The HLA-A:B:DR mismatches included in each group are
as follows:
[0 HLA-DR and 0/1 HLA-B] - 1:0:0, 0:1:0, 1:1:0, 2:0:0, 2:1:0
[0 HLA-DR and 2 HLA-B] or [1 HLA-DR and 0/1 HLA-B]
0:2:0, 1:2:0, 2:2:0, 0:0:1, 1:0:1, 2:0:1, 0:1:1, 1:1:1, 2:1:1
[1 HLA-DR and 2 HLA-B] or [2 HLA-DR]
0:2:1, 1:2:1, 2:2:1, 0:0:2, 1:0:2, 2:0:2, 0:1:2, 1:1:2, 2:1:2, 0:2:2, 1:2:2, 2:2:2.
eeGFR post-transplant calculated from the first biochemical data recorded by the UK Renal Registry following transplantation. Returns are annual for paediatrics
and quarterly for adults
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and changed over time (Fig. 1); although those trans-
planted aged 0–4 years had the least initial graft survival,
by 10 years they had the highest graft survival. Those
transplanted aged 15–19 years had the fastest rate of
transplant failure. At 15 years, those transplanted aged
0–4 years had a survivor function of 71.7% (95% CI 63.4,
78.5) compared to 54.4% (95% CI 49.9, 58.7) for those
transplanted aged 15–19 years, p < 0.0001.
Associations with graft loss from the multivariable
Cox proportional hazards model are shown in Table 2
and visually in Fig. 2. Graft loss varied over the age
spectrum; compared to 25–29 years, being aged 5–9
years was a protective association (HR 0.49 (95% CI
0.33, 0.73), p < 0.0001), whereas young adulthood was a
risk association (15–19 years, HR 1.54 (95% CI 1.29,
1.83), p < 0.0001; 20–24 years, HR 1.41 (95% CI 1.20,
1.67), p < 0.0001). Older age was associated with
reduced risk of graft loss (30–34 years, HR 0.75 (95% CI
0.60, 0.94), p = 0.01). Other protective associations were
having a live donor (HR 0.86 (95% CI 0.76, 0.97), p =
0.01) and higher initial eGFR (per 10 mL/min/1.73m2)
(HR 0.82 (95% CI 0.79, 0.86), p < 0.0001). Risk
associations included female sex (HR 1.13 (95% CI 1.00,
1.28), p = 0.049, adverse HLA mismatches (HR 1.50 (95%
CI 1.19, 1.89), p = 0.001), Black ethnicity (HR 1.51 (95%
CI 1.15, 1.97), p = 0.003), and glomerular diseases (HR
1.30 (95% CI 1.14, 1.48), p < 0.0001). We found no
statistical relationship with time period, calculated
reaction frequency, socio-economic status or pre-
emptive transplantation in multivariable analyses.
Univariable hazard ratios are shown in Supplemental
Table 2. A piecewise model split at one year is shown in
Supplemental Table 3.
Associations with eGFR decline are shown in Table 3
and visually in Fig. 3. Regression coefficients represent
rate of annual eGFR change (mL/min/1.73 m2/year).
Risk associations for eGFR decline included female sex
(− 0.89 mL/min/1.73m2/year (95% CI -1.36, − 0.42), p <
0.0001), glomerular diseases (− 0.95 mL/min/1.73 m2/
year (95% CI -1.47, − 0.44), p < 0.0001), young
adulthood, Black ethnicity and higher initial transplant
function. Compared to being aged 25–29 years, being
aged 15–24 years was associated with eGFR decline
(15–19 years, − 1.27 mL/min/1.73 m2/year (95% CI
-1.99, − 0.54), p = 0.001; 20–24 years, − 1.45 mL/min/
1.73 m2/year (95% CI -2.11, − 0.80), p < 0.0001).
Compared to White, Black ethnicity was associated
with eGFR decline (− 1.52 mL/min/1.73 m2/year (95%
CI -2.67, − 0.38), p = 0.009). Compared to an initial
eGFR of < 60 mL/min/1.73m2, higher initial eGFR was
associated with eGFR decline (60–90 mL/min/1.73m2,
− 0.56 mL/min/1.73 m2/year (95% CI -1.05, − 0.07), p =
0.03); > 90 mL/min/1.73m2, − 3.55 mL/min/1.73 m2/year
(95% CI -4.37, − 2.72), p < 0.0001). A significant
interaction (p < 0.0001) was found between ethnicity
and initial eGFR, with stratum-specific exposure effects
detailed in Table 3. The most clinically relevant was for
Black ethnicity and initial eGFR > 90 mL/min/1.73 m2,
associated with an eGFR decline of − 9.00 mL/min/1.73
m2/year (95% CI -12.6, − 5.44); p < 0.0001. Conversely,
Fig. 1 The youngest age group had the highest initial kidney transplant failure rate but the best long-term transplant survival. Young adults
(aged 15–24 years) had the poorest long-term transplant survival
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there was no statistical difference in rate of eGFR de-
cline for other ethnic groups across initial eGFR
groups. There were no interactions between sex and
primary kidney disease, sex and initial eGFR or ethni-
city and primary kidney disease. Univariable coefficients
are shown in Supplemental Table 4.
Discussion
This study reports long-term graft survival for UK chil-
dren and young adults and evaluates associations with
both transplant failure and eGFR decline. This study
provides an extended follow-up period relative to the
established literature using high-quality linked datasets;
this was necessary to develop a complete dataset of bio-
chemical data and transplant outcomes and enabled
comprehensive analysis of relevant clinical variables. In
addition to being a risk factor for graft loss, it highlights
that young adulthood is associated with eGFR decline in
individuals transplanted before the age of 30 years. Risk
associations for both outcomes included female sex,
young adulthood (15–24 years), glomerular diseases and
Black ethnicity. Initial transplant function was bidirec-
tionally associated with both outcomes, with better ini-
tial function being associated with less risk of graft loss
but a faster rate of eGFR decline. There are scarce data
on eGFR decline among children and young adults, yet
graft health is considered a core outcome for research
[30]. Whilst it might be assumed that risk factors may
be similar for eGFR decline and graft loss, this can now
be confirmed.
Table 2 Multivariable Cox proportional hazards examining associations with death-censored kidney transplant failure in UK patients
transplanted under 30 years of age
Variable Hazard
Ratio
95% confidence interval p-value
Lower Upper
Female sex 1.13 1.00 1.28 0.049
Live donor (cf. deceased donor) 0.86 0.76 0.97 0.01
Human Leucocyte Antigen mismatchesa
[One DR & two B locus OR two DR locus mismatches]
1.50 1.19 1.89 0.001
Higher first reported eGFR post-transplantb
(per 10 mL/min/1.73 m2)
0.82 0.79 0.86 < 0.0001
Glomerular diseasesc, d 1.30 1.14 1.48 < 0.0001
Age group (cf. 25–29 years)e
2–4 0.73 0.44 1.23 0.2
5–9 0.49 0.33 0.73 < 0.0001
10–14 0.93 0.73 1.17 0.5
15–19 1.54 1.29 1.83 < 0.0001
20–24 1.41 1.20 1.67 < 0.0001
30–34 0.75 0.60 0.94 0.01
35–39 0.78 0.54 1.11 0.2
40–44 0.82 0.39 1.70 0.6
Ethnicity (compared to White)
Asian 1.02 0.83 1.24 0.9
Black 1.51 1.15 1.97 0.003
Mixed/Other 1.02 0.71 1.44 0.9
Year of transplant (cf. 1998–2005)
2006–2010 1.05 0.91 1.21 0.5
2011–2014 1.17 0.97 1.42 0.1
Stratified by transplant number in the study period. Standard error adjusted for 4392 clusters
Live donation by ethnic group was as follows: White, 49%; Asian, 32%, Black, 37%; Mixed/Other, 48%
aHLA mismatch groups were derived from the UK 2006 National Kidney Allocation scheme [17]
beGFR post-transplant calculated from the first biochemical data recorded by the UK Renal Registry following transplantation. Returns are annual for paediatrics
and quarterly for adults
cPrimary kidney disease was using a 2012 European coding system [27]. The pediatric diagnosis was used where discordant between pediatric and adult
databases [28]
dThere was non-proportionality over time between those with and without glomerular diseases. Piecewise Cox regression analyses split at 1 year showed similar
effects for glomerular diseases [≤1 year HR 2.05 (1.34, 3.14), p = 0.001; > 1 year HR 1.24 (1.08, 1.43), p = 0.002) and no effect on other HRs; this model presents the
overall HR for the entire follow-up period
eThe 45–49-year age group is suppressed due to small numbers (n = 8)
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This study confirms the association between young
adulthood and graft loss for UK patients. Compared to
25–29 years, being aged 15–24 years is associated with
faster eGFR decline, but children reaching this age have
a higher risk of graft loss, irrespective of time from
transplant. Most UK patients transfer to adult centres at
18 years, suggesting age-related risks are not solely about
transition of care and interventions may be required
across pediatric and adult services. Young adults on
KRT need psychosocial support. Compared to the gen-
eral population, they have impaired relationships, inde-
pendence, employment, quality of life, mental wellbeing
and psychological health [31, 32]. Low medication ad-
herence is common, affecting 43% [33]. Young adults
live with uncertainty, thwarted ambitions, body image is-
sues and social isolation [34]. Healthcare services for
young people vary internationally, with different UK
models proposed [35, 36]. However, UK psychologists
and social worker provision falls short of workforce rec-
ommendations [37, 38].
High rates of graft loss for young patients have
been reported, but with limited follow-up [3]. Five-
year European graft survival for children has been re-
ported at 88% [39]. Our extended follow-up period
enabled observation of better 10-year graft survival
for children aged 0–4 years relative to other age
groups, despite an early increased risk of failure.
Younger patients are more likely to have a live donor
(55% of the 0–4 year age group, compared to 48% of
the 25–29 year age group, p = 0.04) or a deceased
transplant from a younger donor (median donor age
in the 0–4 year age group was 23 years (IQR 23, 41)
compared to 39 years (IQR 24, 50) in the 25–29 year
age group, p < 0.0001). These factors are associated
with a lower risk of graft loss [5, 40, 41]. As would
be expected, young children aged 5–9 were low risk
for death-censored kidney transplant loss. In these
young children medications will be administered by
parents and compliance less likely to be of concern.
Young age may confer an immunological advantage,
with a relatively naïve adaptive immunity more cap-
able of accommodating the foreign graft [42].
Our findings confirm the association of female sex,
Black ethnicity and glomerular diseases with graft loss
[3, 5]. Black ethnicity is associated with poor graft
outcomes in UK adults, although this may be mediated
by reduced access to live donors and HLA mismatching,
perhaps due to inherent biological ethnic differences
[43]. Our study categorised HLA group emphasising
HLA-DR locus mismatches to stratify risk, contrasting
with non-UK studies which tend to report total mis-
matches. Using this classification, we found that adverse
mismatches were associated with graft loss but not with
eGFR decline, possibly due to the rarity of adverse mis-
matches (6%). Whilst shown to be associated with graft
loss in adult populations [44, 45], few studies report the
Fig. 2 An increased hazard ratio of death-censored kidney transplant failure was associated with female sex, deceased kidney donation, lower
initial kidney transplant function, more HLA mismatches, young adulthood (age group 15–24), Black ethnicity and glomerular diseases. N = 4392.
eGFR, estimated glomerular filtration rate; HLA, human leucocyte antigen
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impact of initial transplant function in children and
young adults. One study reported graft survival benefits
with an eGFR ≥30mL/min/1.73 m2 at 6 months post-
transplant, among other factors [46]. Higher initial eGFR
appears protective for graft loss within this population,
independent of HLA mismatching and living donation.
This indicates benefit from good-quality organs and the
need to minimise established factors (e.g. cold ischemic
time) known to negatively impact graft survival.
In the UK, a return to dialysis is estimated to cost an
additional £10,000 per year, however failing grafts may
lead to the need for increased appointments and
psychological support, ongoing immunosuppression,
management of anaemia and metabolic bone disease,
dialysis planning and transplant nephrectomy [47, 48],
as well as frailty, incurring higher costs. In this study, we
also sought to determine factors predictive of eGFR
decline. Contrary to graft loss, which is a late and less
frequent outcome, rate of graft decline is a ‘real-time’
measure often used by clinicians and families to gauge
graft health post-transplant. Although the risk factors
identified are inherently non-modifiable, they can 1) help
clinicians to identify patients who may benefit from en-
hanced care and 2) help patients to understand and
manage expectations of their transplant function. Future
work could include the derivation and validation of a
prognostic tool to allow patients and clinicians to per-
sonalise post-transplant care and alternative approaches
to modelling longitudinal transplant function.
Understanding risk associations for graft loss and
decline could help early identification of patients for
close monitoring, psychosocial support and targeted
intervention. Interventions to structure medication-
taking are needed, since adherence is worse on the
weekend [49]. Among young adults, information
technology-based interventions show promise in
Table 3 Multivariable linear regression examining associations with eGFR decline in UK patients transplanted under 30 years of age
Variable Coefficient 95% confidence interval p-value
Lower Upper
Female sex −0.89 −1.36 −0.42 < 0.0001
Glomerular diseasesa −0.95 − 1.47 − 0.44 < 0.0001
Ethnicity (cf. White)
Asian 0.41 −0.31 1.14 0.3
Black −1.52 −2.67 −0.38 0.009
Mixed/Other 0.42 −0.88 1.71 0.5
First reported eGFR post-transplantb (cf. < 60mL/min/1.73m2)
60–90 −0.56 −1.05 −0.07 0.03
> 90 −3.55 −4.37 −2.72 < 0.0001
Age groupc (cf. 25–29 years)
2–4 −1.73 −3.47 0.01 0.05
5–9 −0.07 −1.16 1.01 0.9
10–14 −0.23 −1.12 0.66 0.6
15–19 −1.27 − 1.99 −0.54 0.001
20–24 −1.45 −2.11 −0.80 < 0.0001
30–34 0.70 −0.07 1.47 0.08
35–39 1.18 −0.04 2.40 0.06
40–44 2.07 −0.54 4.67 0.1
aPrimary kidney disease was using a 2012 European coding system [52]. The pediatric diagnosis was used where discordant between pediatric and adult
databases [28]
beGFR post-transplant calculated from the first biochemical data recorded by the UK Renal Registry following transplantation. Returns are annual for paediatrics
and quarterly for adults. There was evidence of non-linearity between initial eGFR and eGFR decline and therefore data are presented as categorical
cAge at start of eGFR slope analysis. Age range grouped into 5-year bands, however there were no transplants under the age of 2 years
The regression coefficient of the model intercept was −1.54 (95% CI, − 2.08 to − 1.00; p < 0.0001)
There were no interactions between: sex and primary kidney disease, sex and initial eGFR or primary kidney disease and ethnicity. There was a significant
interaction (likelihood ratio test p < 0.0001 between full model and model fitting the interaction term) between initial eGFR and ethnicity. The stratum-specific
exposure effects of initial eGFR and ethnicity (compared with White, eGFR < 60mL/min/1.73 m2) are as follows:
Asian, eGFR 60–90 0.11 (95% CI -1.45, 1.66), p = 0.9
Asian, eGFR > 90 -0.49 (95% CI -2.73, 1.76), p = 0.7
Black, eGFR 60–90 0.30 (95% CI -2.17, 2.77), p = 0.8
Black, eGFR > 90 -9.00 (95% CI -12.6, − 5.44), p < 0.0001
Mixed/Other, eGFR 60–90 -0.34 (95% CI -3.08, 2.40), p = 0.8
Mixed/Other, eGFR > 90 -2.25 (95% CI -6.55, 2.05), p = 0.3
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improving care process self-management outcomes, but
their effect on clinical outcomes is less certain [50]. Fur-
thermore, developmentally appropriate interventions will
need to be considered for this age-range. Worse out-
comes for medication adherence are associated with
mental health problems [33]. For UK patients with de-
pression and a chronic physical health problem, National
Institute for Health and Clinical Excellence (NICE) rec-
ommendations include individual guided self-help
through cognitive behavioural therapy [51]. In the low-
intensity Improving Access to Psychological Therapies
(IAPT) service, a Psychological Wellbeing Practitioner
supports patients with frequent but brief coaching [52].
IAPT is effective; depression and anxiety screening scale
scores fell with treatment, leading to recovery in ~ 55%
of cases. A 5% improvement in employment was ob-
served, associated with lower unemployment benefit
costs and higher taxes from employment [53]. Studies
evaluating the role of psychological therapies in young
adults with transplants are needed.
This is the first UK study to explore risk factors for
graft loss as well as eGFR decline for children and young
adults. The use of high-quality datasets enabled a long
follow-up period, high data completeness and the evalu-
ation of relevant clinic-demographic covariates (exclud-
ing immunosuppression regimes). We included second
and third grafts in our analyses, which affected 15% of
patients. Their inclusion ensures our study population is
representative of the child and young adult KRT popula-
tion in the UK and findings therefore reflect ‘real-world’
data relevant to patients seen in everyday clinical prac-
tice. Differing coding systems may limit international
comparisons. In our Cox model, there was non-
proportionality over time between by kidney disease
group, although similar effects were seen in a piecewise
model. eGFR decline was modelled over the most recent
5 years of data per patient, assuming linearity. This may
not capture the effect of factors associated with initial
eGFR decline and may explain why some factors are not
common to both analyses, such as HLA mismatch and
donor type. Newer alternative techniques, including
Bayesian smoothing, allow analysis of all available eGFR
data, which may be more representative [54]. We
substituted the previous value for missing heights in
children, which assumes no growth, thus underestimat-
ing the eGFR for that time point. However, the regres-
sion line was calculated using all available eGFR data,
making this less of an issue. A higher initial eGFR may
produce a steeper regression slope and possibly explain
these observed associations. The 7-year median follow-
up time did not allow analysis of the impact of transition
age for different age groups at transplant. We did not
conduct a mediation analysis; hence for those variables
with potential mediators, total effects only were mea-
sured. Our eGFR decline model only explained 5% of
the observed variance which may be the result of linear
Fig. 3 eGFR decline was associated with female sex, glomerular diseases, Black ethnicity, young adulthood (age group 15–24) and higher initial
kidney transplant function. N = 4284. The regression coefficient of the model intercept was − 1.54 (95% CI, − 2.08 to − 1.00; p < 0.0001). The
model R2 was 0.04. eGFR, estimated glomerular filtration rate
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eGFR modelling and/or unmeasured variables. We found
an interaction between ethnicity and initial eGFR, where
Black ethnicity and better initial function was associated
with more rapid rate of eGFR decline. This suggests that
this group need careful planning, counselling and clinical
support. More work is required to understand these re-
sults. We were unable to evaluate residual confounders,
such as trends in care such as immunosuppression re-
gimes, surgical advances and kidney allocation policy, al-
though we found no time-period effects in multivariable
analyses. We lacked data on cause of graft loss.
Conclusions
In conclusion, young adulthood is a key risk factor for
transplant loss and eGFR decline for UK children and
young adults. Risk associations common to graft loss
and eGFR decline include female sex, Black ethnicity
and glomerular diseases. A higher initial eGFR was
associated with less risk of graft loss but faster rate of
eGFR decline. It is anticipated that the findings from
this study will support health professionals to accurately
counsel young people about the life expectancy of their
kidney transplant.
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